Freemont Management S.A. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Freemont Management S.A. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, Holdings Channel.com reports. The fund bought 6,600 shares of the biopharmaceutical company’s stock, valued at approximately $5,094,000.

A number of other large investors have also recently made changes to their positions in REGN. WPG Advisers LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Caitlin John LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. FNY Investment Advisers LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $38,000. Finally, Torren Management LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $38,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $719.88 on Thursday. The company has a market cap of $76.11 billion, a price-to-earnings ratio of 17.54, a price-to-earnings-growth ratio of 1.60 and a beta of 0.30. The company has a 50-day moving average price of $747.55 and a 200-day moving average price of $744.35. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the firm posted $8.22 earnings per share. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Royal Bank Of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $826.59.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.